Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Padcev/Keytruda Accepted for Chinese Review for 1st Line Bladder Cancer Use
March 29, 2024
- Sumitomo-Sponsored Trial for Parkinson’s Cell Therapy to Commence in US
March 29, 2024
- Parexel Helping Japan Address Drug Loss with “Ethnobridging” Studies, PI Still a Hurdle
March 29, 2024
- Fuso Says Toray Jacked Up Damage Claim in Remitch Patent Suit
March 28, 2024
- Sosei Group to Be Renamed “Nxera Pharma” from April
March 28, 2024
- Abilify Maintena Gets EU Nod as 1st 2-Month Injectable for Schizophrenia
March 28, 2024
- AstraZeneca’s Japan Sales Up 8.2% in 2023 Despite Nexium Patent Cliff
March 27, 2024
- Incyte Appoints Eiji Ueda as Japan Chief
March 27, 2024
- SanBio to Submit Additional Data to Obtain Approval for Lead Cell Therapy
March 27, 2024
- One Dead after Taking Kobayashi’s Red Yeast Rice Pills
March 27, 2024
- Kobayashi’s Beni Koji Health Damage Reports Trigger Knock-On Recalls
March 27, 2024
- CureApp Files Alcoholism Therapy App in Japan
March 26, 2024
- Eisai Settles Lenvima Patent Suit with Sun Pharma
March 26, 2024
- EMA Panel Gives Go-Ahead for Xtandi Use in Earlier Setting: Astellas
March 26, 2024
- Boehringer’s Brigimadlin Earns Sakigake Designation
March 26, 2024
- Daiichi Sankyo Files MMR Vaccine in Japan
March 26, 2024
- Hospitalized Cases Tied to Kobayashi Pharma’s Supplements Now Up to 26
March 26, 2024
- Lilly, Nippon Shinyaku Pair Up on Blood Cancer Med in Japan
March 26, 2024
- Daiichi Sankyo Eyes 7 Additional Indications for Enhertu by 2026
March 25, 2024
- Ono Hooks Up with Oxford on Drug Discovery Research
March 25, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…